Search

Search Constraints

You searched for: Author/Creator Bodoky, Gyorgy

Search Results

1. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. Issue 4 (1st February 2018)

2. Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. (8th July 2016)

3. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. Issue 3 (10th May 2020)

4. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. Issue 3 (10th May 2020)

5. Expenditures on Oncology Drugs and Cancer Mortality‐to‐Incidence Ratio in Central and Eastern Europe. (4th September 2018)

6. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Issue 7 (July 2021)

7. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). Issue 9 (20th March 2021)

8. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Issue 5 (May 2015)

9. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 3 (March 2019)

10. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Issue 5 (May 2017)